Silence Therapeutics plc, (LON:SLN) a leader in the discovery, delivery, and development of novel RNA therapeutics for the treatment of serious diseases with unmet medical need, announces that the US Patent and Trade Mark Office has issued a notice of allowance for US patent applications 15/589,968 and 15/594,349.
Silence has made the relevant payment of grant fees and normal practice is that the granted patents will now be issued by the US Patent and Trade Mark Office. The allowed claims of both patent applications provide Silence with further protection for its innovative chemical modification technology in the US. Silence
believes these allowed claims are relevant to third party medicines in ongoing clinical trials.
Ali Mortazavi, Chief Executive Officer of Silence Therapeutics Plc, commented: “The two additional patent applications that have been allowed for grant by the US Patent and Trade Mark Office provide further protection for our US patent estate. With the grant of these, and other recently allowed US patent applications, we will have nine granted US patents, one US patent application, three granted European patents and four European patent applications encompassing our chemical modification technology. We continue to believe that several third party late‐stage clinical RNAi candidates require licences under our patent portfolio and that such licences could have a material financial effect on Silence.”
